Moi University Open Access Repository

Disclosure of HSV-2 serological test results in the context of an adolescent HIV prevention trial in Kenya

Show simple item record

dc.contributor.author Mbai, Isabella
dc.date.accessioned 2021-06-10T06:15:29Z
dc.date.available 2021-06-10T06:15:29Z
dc.date.issued 2015
dc.identifier.uri https://sti.bmj.com/content/91/6/395
dc.identifier.uri http://ir.mu.ac.ke:8080/jspui/handle/123456789/4605
dc.description.abstract Objectives Herpes simplex virus type 2 (HSV-2) biomarkers are often used in adolescent sub-Saharan HIV prevention studies, but evaluations of test performance and disclosure outcomes are rare in the published literature. Therefore, we investigated the proportion of ELISA-positive and indeterminate samples confirmed by western blot (WB), the psychosocial response to disclosure and whether reports of sexual behaviour and HSV-2 symptoms are consistent with WB confirmatory results among adolescent orphans in Kenya. Methods In 2011, 837 Kenyan orphan youth in grades 7 and 8 enrolled in an HIV prevention clinical trial with HSV-2 biomarker outcomes. We used a modified algorithm for the Kalon HSV-2 ELISA to improve specificity; positive and indeterminate results were WB tested. We developed culturally sensitive protocols for disclosing positive results, and documented psychosocial responses, reports of sexual contact and HSV-2 symptoms. Results 28 adolescents (3.3%) were identified as HSV-2 seropositive, six as indeterminate. Of these, 22 positive and all indeterminates were WB tested; 20 and 5, respectively, were confirmed positive. Most youth reported moderate brief stress after disclosure; 22% reported longer and more severe distress. Boys were more likely to be in the latter category. Self-reported virginity was highly inconsistent with WB-confirmed positives. Conclusions The higher than manufacturer's cut-off for Kalon ELISA modestly reduced the rate of false-positive test results, but also increased false negatives. Investigators should consider the risk:benefit ratio in deciding whether or not to disclose HSV-2 results to adolescent participants under specific field conditions en_US
dc.language.iso en en_US
dc.publisher BMJ Publishing Group Ltd en_US
dc.subject HSV-2 serological test en_US
dc.subject Adolescent en_US
dc.subject HIV en_US
dc.title Disclosure of HSV-2 serological test results in the context of an adolescent HIV prevention trial in Kenya en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account